Skip to search formSkip to main contentSkip to account menu

teprotumumab

Known as: Immunoglobulin G1, Anti-(Human Insulin-like Growth Factor I Receptor)(Human Monoclonal Heavy Chain), Disulfide with Human Monoclonal Light Chain, Dimer 
A recombinant, fully human monoclonal antibody directed against the insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

4 relations
NCIt Antineoplastic Agent Terminologyantigen binding

Narrower (2)

R 1507RV001

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Teprotumumab. Anti-insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, Treatment of thyroid eye disease
2020
2020
New product intros [almonertinib, bempedoic acid (first-in-class), cetirizine hydrochloride (new formulation), calaspargase pegol-mknl, eptinezumab-jjmr, lumateperone tosylate, luspatercept (new…
2018
2018
Considering use of teprotumumab in thyroid eye disease patients
2017
2017
Teprotumumab reduziert endokrine Orbitopathie
Der insulinähnliche Wachstumsfaktor 1 (IGF-1) verstärkt synergistisch die Wirkung des schilddrüsenstimulierenden Hormons. Bei…